Best Pharma & Healthcare Funds
Defensive-growth exposure to pharma, hospitals and diagnostics.
Data updated · 19 direct-growth funds ranked by a transparent 0–100 Smart Score
| ⚖ VS | Fund | Score ↓ | Verdict | 1Y | 3Y | 5Y | Sharpe | Sortino | Std Dev | Alpha | Beta | VR★ | P/E | Expense | AUM | Age |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SBI Healthcare Opportunities SBI | 82 | Strong Buy | 26.1% | 24.6% | 20.7% | 1.23 | 1.95 | 14.4 | 5.3 | 0.83 | — | 58.1 | 1.00% | ₹6.1k Cr | 13.9y | |
| HDFC Pharma And Healthcare HDFC | 79 | Strong Buy | 31.6% | 30.6% | — | 1.40 | 2.40 | 16.2 | 8.9 | 0.91 | — | 49.5 | 1.04% | ₹3.7k Cr | 3.1y | |
| Mirae Asset Healthcare Mirae Asset | 73 | Buy | 28.1% | 23.7% | 17.8% | 1.09 | 1.71 | 16.0 | 3.4 | 0.93 | — | 48.7 | 0.61% | ₹3.6k Cr | 8.5y | |
| Kotak Healthcare Kotak | 72 | Buy | 33.1% | — | — | 1.17 | 1.67 | 14.6 | 14.8 | 0.68 | — | 51.4 | 1.03% | ₹859 Cr | 2.9y | |
| UTI Healthcare UTI | 59 | Hold | 22.0% | 23.1% | 17.7% | 1.06 | 1.71 | 16.0 | 3.5 | 0.90 | — | 40.3 | 1.34% | ₹1.4k Cr | 13.9y | |
| DSP Healthcare DSP | 58 | Hold | 19.1% | 20.6% | 16.9% | 1.01 | 1.54 | 15.1 | 3.2 | 0.80 | — | 36.2 | 0.75% | ₹3.7k Cr | 8.0y | |
| ICICI Pru Healthcare ICICI Pru | 54 | Hold | 10.6% | 21.6% | 18.3% | 0.99 | — | 16.2 | 2.4 | 0.91 | — | — | 1.30% | ₹7.1k Cr | 8.4y | |
| WhiteOak Capital Pharma And Heathcare WhiteOak | 52 | Hold | 26.2% | — | — | — | — | — | — | — | — | 51.8 | 1.07% | ₹964 Cr | 2.8y | |
| PGIM India Healthcare PGIM India | 50 | Hold | 26.4% | — | — | 0.59 | 0.82 | 13.3 | 10.0 | 0.64 | — | 50.3 | 0.98% | ₹142 Cr | 2.0y | |
| Bajaj Finserv Healthcare Bajaj Finserv | 45 | Hold | 24.2% | — | — | 0.41 | 0.57 | 13.7 | 6.1 | 0.68 | — | 48.1 | 0.90% | ₹419 Cr | 1.9y | |
| ABSL Pharma And Healthcare Aditya Birla Sun Life | 41 | Avoid | 19.4% | 19.9% | 15.9% | 0.97 | 1.49 | 15.4 | 1.4 | 0.90 | — | 48.3 | 1.05% | ₹1.1k Cr | 7.4y | |
| Tata India Pharma & Healthcare Tata | 40 | Avoid | 10.7% | 18.4% | 15.8% | 0.89 | 1.26 | 13.4 | 7.8 | 0.62 | — | 40.6 | 1.09% | ₹1.5k Cr | 10.9y | |
| Nippon India Pharma Nippon India | 39 | Avoid | 14.1% | 17.8% | 15.2% | 0.85 | 1.22 | 13.1 | 7.3 | 0.59 | — | 38.6 | 0.99% | ₹9.1k Cr | 13.9y | |
| Invesco India Pharma and Healthcare Invesco | 34 | Avoid | — | — | — | — | — | — | — | — | — | 67.3 | — | ₹474 Cr | 0.2y | |
| Baroda BNP Paribas Health And Wellness Baroda BNP Paribas | 33 | Avoid | 16.0% | — | — | 0.18 | 0.26 | 12.0 | 4.4 | 0.57 | — | 44.7 | 1.47% | ₹478 Cr | 1.4y | |
| LIC MF Healthcare LIC | 31 | Avoid | 18.3% | 21.4% | 14.8% | 0.99 | 1.49 | 16.2 | 2.6 | 0.89 | — | 53.6 | 1.38% | ₹97 Cr | 7.7y | |
| ITI Pharma And Healthcare ITI | 28 | Avoid | 17.1% | 19.9% | 15.6% | 0.87 | 1.29 | 16.5 | 0.3 | 0.94 | — | 48.3 | 0.89% | ₹267 Cr | 5.0y | |
| Bandhan Healthcare Bandhan | 25 | Avoid | — | — | — | — | — | — | — | — | — | 39.1 | 1.25% | ₹325 Cr | 1.0y | |
| Quant Healthcare Quant | 23 | Avoid | 19.9% | 20.1% | — | 0.85 | 1.08 | 18.2 | 2.3 | 0.88 | — | 28.1 | 1.62% | ₹416 Cr | 3.4y |
Pharma & Healthcare funds — quick answers
›Which is the best Pharma & Healthcare mutual fund right now?
SBI Healthcare Opportunities currently ranks #1 of 19 Pharma & Healthcare funds with a FundLens Smart Score of 82/100 (Strong Buy). It returned 24.6% over 3 years and 20.7% over 5 years at a 1.00% expense ratio (direct plan). Rankings are recomputed from data updated 20 Nov 2026.
›Which Pharma & Healthcare fund has the best risk-adjusted returns?
HDFC Pharma And Healthcare leads the category on the Sortino ratio at 2.40 (Sharpe 1.40) — meaning it has delivered the most return per unit of downside risk among Pharma & Healthcare funds.
›Which Pharma & Healthcare fund has the lowest expense ratio?
Mirae Asset Healthcare charges 0.61% a year (direct plan) — the lowest in the category. Lower fees compound in your favour over long holding periods.
›Which is the smallest Pharma & Healthcare fund by AUM?
LIC MF Healthcare manages ₹97 Cr, the smallest in the category. Smaller funds can be nimbler, but check track record and costs before treating size alone as an edge.
›How long should I stay invested in a Pharma & Healthcare fund?
Pharma & Healthcare funds carry very high risk, so a horizon of 7+ years is generally sensible. Defensive-growth exposure to pharma, hospitals and diagnostics. This is research, not investment advice.
Want these answers conversationally? Ask FundLens · New to the ratios? Sharpe vs Sortino, explained